|
|
Post by cretin11 on Nov 27, 2023 12:48:57 GMT -5
It's hard not to be shocked by the number of shares our CEO has sold this year. Wish my shares had a basis of $0 like his. Between short sellers and CEO's this has been a very rough road. I agree with you, but we seem to be in the minority on this board. Also notable that no matter how low our share price has gone this year, we haven't heard of our ceo or any execs buying shares on the open market. People have countered that by saying "they already have so many shares" but I'm still not convinced that's a great thing (for us regular shareholders i mean). We had some share purchases by insiders a while back when our share price was in the $2s, have there been any since then? |
|
|
|
Post by peppy on Nov 27, 2023 12:59:24 GMT -5
It's hard not to be shocked by the number of shares our CEO has sold this year. Wish my shares had a basis of $0 like his. Between short sellers and CEO's this has been a very rough road. I agree with you, but we seem to be in the minority on this board. Also notable that no matter how low our share price has gone this year, we haven't heard of our ceo or any execs buying shares on the open market. People have countered that by saying "they already have so many shares" but I'm still not convinced that's a great thing (for us regular shareholders i mean). We had some share purchases by insiders a while back when our share price was in the $2s, have there been any since then? Cretin, did you somehow move wmdhunt post from the "Possible reasons MNKD is being walked down to $3.50?" thread to this one? Was this to repeat the point? Recall a divorce. |
|
|
|
Optimism
Nov 27, 2023 13:42:57 GMT -5
via mobile
Post by cretin11 on Nov 27, 2023 13:42:57 GMT -5
No I didn’t move it, just replied on this thread where it was posted. Perhaps it was moved by the original poster.
|
|
|
|
Post by prcgorman2 on Nov 27, 2023 13:47:32 GMT -5
I'm not shocked or dismayed no matter how many threads wmdhunt's FUD gets repeated in.
I'm not at all surprised cretin11 would re-post and re-spond as executive compensation is one of his favorite harangues. So be it. With all of the bellyaching, I've yet to see any unbiased (or even biased) salary and compensation information for executives in small-ish (~$1B market cap) biopharmaceutical companies. I assume MannKind executive compensation is in range unless someone can show empirical evidence to the contrary.
|
|
|
|
Post by peppy on Nov 27, 2023 13:51:16 GMT -5
No I didn’t move it, just replied on this thread where it was posted. Perhaps it was moved by the original poster. I looked once more. I do not see that post from wmdhunt on this thread. I do read the same post on mnkd.proboards.com/post/258362/thread. Let me know if I need medical attention. I made another mistake today.  |
|
|
|
Post by BD on Nov 27, 2023 13:51:41 GMT -5
Non-staffers can't "move" a post.
|
|
|
|
Post by liane on Nov 27, 2023 14:05:20 GMT -5
I removed a duplicate post - no need to post the same thing twice.
|
|
|
|
Post by akemp3000 on Nov 27, 2023 17:34:19 GMT -5
Why is it difficult to understand that a divorce caused the selling of a small percentage of the stock the CEO owns. This is likely the same reason he's not currently buying new shares on the open market as that would make no sense at all. This dead horse has been sufficiently beaten.
|
|
|
|
Post by sportsrancho on Nov 28, 2023 8:11:43 GMT -5
It doesn’t matter why, it sends a bearish sentiment..just like buying sends a bullish one.
|
|
|
|
Post by prcgorman2 on Nov 28, 2023 8:46:16 GMT -5
It doesn’t matter why? Tell the analysts that. Again, the evaluation of buying and selling has to be done on a comparative basis, just like buying and selling of real estate. The bearish or bullish “signal” you refer to might matter to retail investors, but it is the institutional investors that are controlling the share price. I’m not going to say executive compensation and buying/selling doesn’t matter, but only that generally it doesn’t matter very much and certainly not as much as retail investors think it does.
|
|
|
|
Post by cretin11 on Nov 28, 2023 8:57:56 GMT -5
Funny, I recall when we last had our execs buying shares on the open market (seems like a long time ago, but it did happen), the same people who say share sales don’t matter were singing a different tune.
If I recall, our shares were in the $2s then. Is that the price at which our trusted leaders feel is appropriate to buy?
Sports is correct, it doesn’t matter the reason, selling shares sends a bearish signal and buying does the opposite. Our share price movement has supported that notion in both instances.
|
|
|
|
Post by sportsrancho on Nov 28, 2023 10:19:12 GMT -5
I think it keeps new investors from buying.
I can’t speculate it’s because of a divorce.
It could be because he thinks a recession is on the way. It’s not a criticism.
|
|
bkdmd
Researcher
Posts: 79
|
Post by bkdmd on Nov 28, 2023 13:36:38 GMT -5
Since 2000 OVER 50% of the companies that were in the S&P 500 at that time have been bought out, merged, gone bankrupt, or ceased to exist.
Since the 1990's we have lost over 50% of the public traded companies. (from 8000 in 1990 to 3700 today)
Maybe the CEO doesn't have confidence in himself.
|
|
|
|
Post by hellodolly on Nov 28, 2023 15:30:52 GMT -5
Since 2000 OVER 50% of the companies that were in the S&P 500 at that time have been bought out, merged, gone bankrupt, or ceased to exist. Since the 1990's we have lost over 50% of the public traded companies. (from 8000 in 1990 to 3700 today) Maybe the CEO doesn't have confidence in himself. Read carefully for that lack of confidence in himself. Maybe "maybe' is your out? It's never been a better time for MannKind employees, shareholders and partners. We're in the strongest position we've been and we're well diversified as we look out whether it's our inline brand opportunities or pipeline opportunities or Tyvaso DPI growth in addition to any other business development things that come our way. We're super excited at the orphan lung business as we look at IPF and specifically nintedanib and the TGF-beta programs. These are programs that have moved up in the priority list in terms of treatments coming down the pipeline in IPF as we've had so many failures, which is not good for patients but unfortunately good for MannKind as we are now closer than ever to help more people in IPF. We feel very strongly that MannKind-201 can provide a differentiated product for those people and the drug that's already approved on the market. But lowering the dose and deliver directly into the lung we think will provide a huge benefit around the GI side effects and hopefully efficacy as people can dose higher. There's been over $400 million in the last year just in funding an ALK-5 inhibitor as well as other inhaled therapeutics around the nintedanib or [indiscernible]. As we look at the next three quarters, I want to share with you the endocrine updates here as well as orphan lung. Our 2024 milestones will be shared on the next call, but for now, today, as we look out this year, we've completed everything we've said we are and we're on track to wrap up the year strong. Andy is on track to file our -- their regulatory submission there for India, which will be an approval if all goes well in 2024. INHALE-1 will be fully randomized and hopefully reading out sometime next year and INHALE-3 will be read out hopefully by March-April time frame. On the orphan lung, 101 is on track for submission. We expect to initiate that trial in Q2 and 201 IND submissions on track and we'll be doing that study in Phase 1 healthy volunteers early next year. We've never -- we've been near death and we take seriously our fiduciary responsibility to shareholders. As we think about our future expense management, capital allocation is the number one most critical thing we have to do, which is really about deleveraging the company, investing in our growth drivers and improving shareholder value. Here are many shots on goal to think about as we close up today's call and get ready for Q&A. Number one, pipeline is 101, nintedanib is a real unmet need. And just to put some context here, for every 1,000 patients we get, it's approximately $100 million in revenue. MannKind-201 has huge upside until we get this through Phase 1, I don't want to guess how big this could be, but it could be a nice huge inflection for our company and our patients. Tyvaso DPI, we can't always guess where that will be, but as you know, UT has a goal for 25,000 patients in '25 and shareholders can guess it's at 10,000, 20,000, what that means for Tyvaso. What does mean is $250 million to $300 million in revenue for every 10,000 covered patients. We're super excited and anxious to await the UT TETON study readouts for IPF. And as we get really excited now about our pediatric INHALE-1, continued V-Go stabilization and hopefully growth, and our pump-sparing trial on INHALE-3, as well as an opportunity to bring a fresh set of patients around the world. Thank you again for your patience. It's been a long quarter and apologize about our stock price. Not anything we can see what caused a decline the last day or so, but we'll continue to progress and everything we can to make this a great company and a great investment for shareholders. Source: November 2023 Earnings call |
|
|
|
Post by radgray68 on Nov 28, 2023 15:46:51 GMT -5
Yeah, Scary stuff. He basically announced our eminent closure. So deflated. Tough to watch a CEO just giving up like that. (Dripping with sarcasm)
|
|
